FLIR Systems (FLIR) Trims Guidance, Shares Plunge

Joel Anderson |

Thermal imaging manufacturer FLIR Systems (FLIR) took a hard hit on Tuesday after it reported preliminary earnings for the third quarter of 2013. The company cut its full-year guidance and showed lower-than-expected earnings. Shares declined almost 14 percent on the news.

Reliance on Government Markets Hurts Earnings

FLIR reported that weakness in those markets with exposure to the federal government drove a drop in profits below their expectations. FLIR now expects to report revenues of $358 million to $360 million, or $0.32 to $0.33 per share, for the quarter ending on September 30, 2013. This means full-year 2013 revenue projections have been reduced to $1.45 billion to $1.5 billion, or $1.38 to $1.45 per share, down from previously reported guidance of $1.5 billion to $1.6 billion, or $1.56 to $1.66 per share.

"While we are disappointed in the preliminary results for the third quarter, we have also taken steps, above and beyond those related to our strategic review, to reduce costs in response to the current operating environment, and we remain highly confident in our strategy and outlook for the future," said CEO Andy Teich. "Ongoing uncertainty in the U.S. government is likely to continue to affect our performance in the fourth quarter, and our revised guidance is intended to reflect this environment. We believe our CDMQ(R) strategy is the best alternative for government customers to acquire high performance intelligence, surveillance, reconnaissance, targeting, and detection capabilities with low cost, high quality, and outstanding value. We remain very enthusiastic about the opportunities in our commercial business in 2014 and beyond, and are committed to continuing to innovate for our customers and deliver value to our shareholders, as illustrated by our recent new product introductions and today's strategic business realignment."

Realigning Facilities

FLIR also reported that it would be closing as many as six of its not-to-scale sites and shifting production to other, larger facilities.

"The realignment of operations announced today is the culmination of a strategic operations review we began this past summer to further enhance operating efficiency and profitability and to improve our internal execution with better communication, collaboration, and cooperation across the company," said Teich.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Spotlight

BiondVax Pharmaceuticals Ltd.

Biondvax Pharmaceuticals Ltd Ltd is a clinical stage biopharmaceutical company. The Company is engaged in developing, manufacturing and commercializing immunomodulation therapies for infectious diseases.

Events

EQUITIES Emerging Growth and Innovation Forum

EQUITIES Inaugural Emerging Growth and Innovation Forum at Disruptive firm MRY New York City's Flatiron District. The forum is on February 24th from 12:00 pm to 6:00 pm with a…

Learn more

Research

MagneGas Corporation (MNGA)

MagneGas Corporation is an alternative energy company that creates a system that produces hydrogen based fuel through the gasification and sterilization of liquid and liquid waste. ($49 USD)

Learn more

Private Markets

SU Labs Accelerator Seed Fund

We're a fiercely passionate community of entrepreneurs leveraging rapidly accelerating technologies to create a brighter future. Join us in fostering innovation, driving impact and funding the future.

FAB Financial Inc.

Banking is broken. Years ago people who needed business advice would turn to their local bank manager for help. The banker was thought of as a trusted member of the…